ArticleScientific reports2026
Epidemiologic survey of ulcerative colitis and crohn's disease in Japan using claim data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Nanomaterial Platform for Inflammatory Bowel Disease: Three-Dimensional Integration of Delivery Mechanism, Therapeutic Drug Delivery and Intelligent Material Design.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We aimed to clarify the status of ulcerative colitis (UC) and Crohn's Disease (CD), identify the proportion of patients who visited only clinics, and obtain data to support the nationwide survey using a claims database including records of hospital and clinic visits. An epidemiological survey of hospitals and clinics was conducted using a nationwide claims database to estimate the prevalences of UC and CD in the same year as the nationwide survey. The proportion of patients who visited only clinics was calculated. Patients with UC were divided into two groups: those who visited only clinics and those who visited hospitals. UC and CD prevalence rates per 100,000 population were 227.9 and 58.2, respectively. Approximately 35% and 12% of patients with UC and CD, respectively, visited only clinics. Multivariate logistic regression analysis adjusted for patient background showed that patients who visited only clinics were older, had milder comorbidities, and incurred lower UC treatment costs than patients who visited hospitals. Epidemiological surveys using the claims database revealed that 35% of patients with UC visited only clinics. Therefore, the actual prevalence rates of patients with UC are expected to be higher than those reported in the nationwide survey, which included only hospital visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.